Stem cell genetics laboratory

Goldshtein Dmitry Vadimovich

Doctor of biological science


Bukharova Tatiana Borisovna – leading researcher, Candidate of biological science
Efremova Anna Sergeyevna –
senior researcher, Candidate of biological science
Makhnach Oleg Vladimirovich – senior researcher, Candidate of Chemical science
Vasilyev Andrey Vyacheslavovich - senior researcher, Candidate of medical science
Galitsyna Elena Valeryevna – post-graduate student, junior research fellow
Leonov Georgy Evgenyevich – resident, junior research fellow
Salikhova Diana Irekovna - junior research fellow
Rzhaninov Evgeny Stanislavovich – highest quality engineer
Bulatenko Natalia Vadimovna – laboratory assistant


Tel. +7(499)324-20-24


Main publications

Project implementation under Grant Agreement №14.604.21.0184 dated 26 September 2017 with the Ministry of Education and Science of Russia according to the federal target program “Research and Development in priority areas of development of the Russian Scientific and technological Complex for 2014-2020” with a purpose of Development of a personalized nootropic drug derived from human induced pluripotent stem cells >>>.

The Stem Cell Genetics Laboratory was set up in 2008. The Laboratory focuses on the development of new technologies and biomedical cell products based on human stem/progenitor cells for regenerative medicine, as well as therapy, diagnosis and adjustment of medication for hereditary diseases.

Since its foundation, the Laboratory has worked on development of new therapeutic approaches for reparative osteogenesis using tissue engineering constructions (TEC) based on osteoprogenator cells and osteoplastic materials, which may include protein factors or gene constructs with osteoinductive action. A cryobank of cell cultures of multipotent mesenchymal stromal cells (MMSCs) obtained from various sources — bone marrow, adipose tissue, umbilical cord vessels, tooth pulp of humans and animals.

The effect of bone inducers such as dexamethasone, dihydroxyvitamin D3 and bone morphogenetic protein BMP-2 on MMSC cultures was studied. The efficacy of using TECs based on MMSCs that were pre-differentiated in the osteogenic direction is shown in vivo in models of heterotopic osteogenesis and during transplantation into the area of bone defects. MMSC-based TEC from a pulp of fallen out milk teeth has been successfully tested for pulp tissue regeneration.

Osteoplastic materials based on polymers of natural and synthetic origin - collagen, chitosan, polylactic and polyglycolic acids, in the form of porous matrices obtained by foaming, laser sintering, 3D printing, and in the form of thermosetting hydrogels are used as cells matrices. Methods of obtaining the materials provide the possibility of impregnation of biologically active substances, which effect is aimed at reducing inflammatory reactions during implantation, enhancing vascularization and osteoinductive action in order to increase the regenerative potential of TEC. The use of non-steroidal anti-inflammatory ibuprofen as part of polylactide matrices significantly increases cell survival during allogeneic transplantation into the bone defect area, ensuring the development of direct osteogenesis without cartilage tissue formation (indirect osteogenesis) and as a result, significantly accelerates the repair and restoration of functionally active bone tissue. TEC uses platelet-rich plasma - a rich source of growth factors, such as FGF, VEGF, PDGF, EGF, and others, providing neovasculogenesis inside the TEC and attracting resident predecessors.

A method of gene therapy ex vivo was developed. MMSCs of adipose tissue were transduced with adenoviral constructs carrying BMP-2 gene. Transplantation of tissue engineering constructions with transduced cells leads to long-term production of a target protein, which ensures a high therapeutic effect of such product. The role of non-coding RNAs in the regulation of osteogenesis is analyzed to increase the efficiency of osteogenic differentiation. New gene products for reparative osteogenesis are being developed using transient viral constructs and plasmid vectors with high transfection efficiency.

In 2018, the Stem Cell Genetics Laboratory introduced a method for obtaining organelles stable cultures from human intestinal biopsies. Intestinal organelles imitate the structure of intestinal epithelium, and formed by several cell types and therefore they are miniaturized and simplified versions of the organ in vitro. The use of organoids provides the opportunity to treat many diseases, to create and test new drugs. The Laboratory implements and optimizes medical technology for the use of intestinal organoids for the selection of personalized cystic fibrosis therapy, which diagnosis and treatment significantly complicates the allelic heterogeneity of CFTR. The in vitro test bases on obtaining organoids from a patient's intestinal biopsy material and treating them with forskolin. The effectiveness of targeted drugs in patients with cystic fibrosis in Russia, including those with rare and unique mutations of CFTR gene, will be assessed using this approach. A cryobank with intestinal organoids was created, which is replenished with new unique cultures. The Laboratory collaborates with the forskolin test developers from the University Medical Center Utrecht in the Netherlands (Molecular cystic fibrosis laboratory of the University Medical Center Utrecht).

The Stem Cell Genetics Laboratory is implementing a project on developing a new nootropic drug based on juvenile neuropeptides derived from the human induced pluripotent stem cells (IPSC). Unlike the currently existing drugs from xenogenic animal tissues, this medication will contain allogeneic or autologous components, which will ensure its low immunogenicity while retaining full-length peptides with pronounced functional activity

The Stem Cell Genetics Laboratory participates in the implementation of multidisciplinary research projects supported by the Russian Science Scientific Foundation and the Russian Federation Ministry of Science grants, in collaboration with research teams from the Kurchatov Institute National Research Center, Central Research Institute of Dentistry and Oral and Maxillofacial Surgery under the Ministry of Health, the Federal Research Center for Crystallography and Photonics RAS, Scientific Research Institute of Human Morphology and others.

Four theses for candidate degree were defended based on the research materials of the Laboratory.